Debiopharm Group, a Swiss-based global biopharmaceutical group of companies, has named a number of management figures to key positions.
Dr. Kamel Besseghir, Debiopharm S.A. CEO since 2006, will chair both Strategy Committee and Development Committee starting Jan. 1, 2012.
Succeeding him as CEO of Debiopharm S.A. will be Dr. Bertrand Ducrey, currently CEO of Debio R.P.
Dr. Cedric Sager will become CEO of Debio R.P. Currently he is manufacturing director.
"One of the main tasks of the individuals we have appointed to these key positions will be to put in place Debiopharm's flagship project to bring down costs and reduce the development period of our drugs whilst maintaining our extremely rigorous standards in respect of quality," said Dr. Rolland-Yves Mauvernay, founder and president of Debiopharm Group.